1Sonnenborn U, Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic [ J ]. Microb Ecol Health Dis,2009,21 : 122 - 158.
2Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity [Jl. Plos ONE ,2007,2 : e1308.
3Kruis W,Schutz E,Fric P,et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis [ J ]. Aliment Pharmacol Ther, 1997,11 : 853 - 858.
4Rembacken JB, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative co- litis : a randomised trial [ J]. Lancet, 1999,354:635.
5Kruis W, Fric P, Pohrotnicks J, et al. Maintaining remission of ulcer- ative colitis with the probiotic Eschefichia coli Nissle 1917 is as ef- fective as with standard mesalazine [ J ]. Gut, 2004,53 : 1617 - 1623.
6Mfillenbrink M, Bruckschen E. Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. eoli Nissle 1917 strain [ J]. Med Klin,1994,89:587 -593.
7Henker J, Laass M, Blokhin BM, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and tod- dlers. [ J 1. Eur J Pediatr,2007 ,166 :311 - 318.
8Henker J, Laass M, Blokhin BM, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers [ J ]. Pediatr Infect Dis J, 2008,27:494 -499.
9Stritzker J, Weibel S, Hill PJ, et al. Tumor-specific colonization, tis- sue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice [ J 1. Int J Med Microbiol,2007,297 ( 3 ) : 151 - 162.
10Brader P, Stritzker J, Riedl CC Jochen S, et al. Escherichia coli Nissle 1917 Facilitates Tumor Detection by Positron Emission Tomography and Optical Imaging [ J ]. Clin Cancer Res ,2008,14 : 2295 - 2302.
